MyShare
Key factors
| sym | BCTX |
| exch | US |
| MCap | 34.32M |
| Beta | 1.754 |
| EPS | -0.79 |
| Div date | 0000-00-00 |
Yesterday
| sym | BCTX |
| exch | US |
| close | 2.19 |
| 50 Day MA | 3.011 |
| 200 Day MA | 4.832 |
| 52 Week High | 7.517 |
| 52 Week Low | 2.01 |
| Target Price | 18.0 |
| Market Cap Mln | 34.32 |
Share statistics
| Shares Outstanding | 15.98M |
| Shares Float | 11.63M |
| Percent Institutions | 13.78 |
| PercentInsiders | 12.27 |
| SharesShort | 677.90K |
| Short Ratio | 6.14 |
| Shares Short Prior Month | 733.31K |
| Short Percent | 4.839 |
Income
| EBITDA | -31.7M |
| Diluted Eps TTM | -0.79 |
earning
| EPS Estimate Current Quarter | -0.2 |
| EPS Estimate Current Year | -1.39 |
| EPS Estimate Next Year | -1.4 |
| Earnings Share | -0.79 |
Dividend
| Dividend Date | 2020-01-02 |
| Last Split Date | 2020-01-02 |
| Last Split Factor | 1:300 |
business
| Enterprise Value Ebitda | -1.16 |
| Book Value /share | -0.50 |
| Price Book MRQ | 17.03 |
| ReturnOnAssetsTTM | -0.85 |
| ReturnOnEquityTTM | -2.06 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Biotechnology |
| Gic Sector | Health Care |
| Gic Sub Industry | Biotechnology |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | CA10778Y3023 |
| CIK | 1610820 |
| Code | BCTX |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-04-19 |
info
| Fiscal Year End | July |
| Full Time Employees | 16.0 |
| IPODate | 2021-02-24 |
| MostRecent Quarter | 2024-01-31 |
Contact
| Name | Briacell Therapeutics Corp |
| Address | Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 |
| Country Name | USA |
| Phone | 604 921 1810 |
| Web URL | https://briacell.com |
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.